Omecamtiv Mecarbil Post-trial Access Study

- Participant has provided GALACTIC-HF PTA informed consent prior to initiation of any study specific activities/procedures. - Participant has completed GALACTIC-HF.

- Investigational product was permanently discontinued during GALACTIC-HF due to protocol-specified reason. - Female participant is pregnant or breastfeeding or planning to become pregnant or breastfeed during treatment and for an additional 5 days after the last dose of treatment. - Female participants of childbearing potential unwilling to use 2 acceptable methods of effective contraception during treatment with OM and for an additional 5 days after the last dose of treatment. - Female participants of childbearing potential with a positive pregnancy test assessed on day 1 by a urine pregnancy test. - Participant has known sensitivity to any of the products or components to be administered during dosing. - History or evidence of any clinically significant disorder, condition or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures or completion.